29 articles with Xellia Pharmaceuticals
Xellia Pharmaceuticals Launches New Doses of VANCO READYTM (Ready-to-use Room Temperature Premixed Vancomycin Injection Bags)
Xellia Pharmaceuticals (‘Xellia’), a global leader in the manufacturing of specialty anti-infective treatments, is launching three new doses of VANCO READYTM, expanding its range of room temperature stable, ready-to-use (RTU) Vancomycin injection premix bags.
Xellia Pharmaceuticals Expands Approved Doses of VANCO READYTM (Ready-to-Use Premixed Vancomycin Injection Bags)
Xellia Pharmaceuticals Expands Approved Doses of VANCO READY TM (Ready-to-Use Premixed Vancomycin Injection Bags) Additional room temperature stable Vancomycin Injection Premix doses now approved in the US, and available in October 2020 Doses of 1.25 g, 1.75 g and 750 mg ready-to-use Vancomycin premixes In total, 7 VANCO READY TM doses now US FDA approved COPENHAGEN, Denmark--( BUSINESS WIRE )-- Xellia Pharmaceuticals (‘X
Xellia Pharmaceuticals, a specialty pharmaceutical company focusing on providing important anti-infective treatments against serious and often life-threatening infections, has received approval from the US Food and Drug Administration allowing the Company to commence manufacturing of drug products at its Cleveland, Ohio site.
California, Other States and Organizations Develop Schemes to Enter Generic Market and Drive Down...
1/10/2020The State of California is considering a measure to sell its own brand of generic drugs in an effort to get in on those cost-savings. California’s Gov. Gavin Newsom is expected to reveal the scheme today in his new state budget.
Xellia Pharmaceuticals Expands Available Doses of VANCO READYTM in the US (Ready-to-Use Premixed Vancomycin Injection Bags)
Room temperature stable Vancomycin injection premix dose of 500 mg in 100 mL ready-to-use bag is now available for purchase in the US
Secured leading US market position in generic anti-infective portfolio
Today, Civica Rx announced it had inked a product supply agreement with Xellia Pharmaceuticals, where Xellia will manufacture essential antibiotics, including Vancomycin and Daptomycin, for Civica’s members.
Civica Rx (Civica, Inc.) and Xellia Pharmaceuticals today announced they have signed a product supply agreement under which Xellia will manufacture essential antibiotics, including Vancomycin and Daptomycin, for Civica’s member health systems.
Nichi-Iko Pharmaceutical Co., Ltd. and Sagent Pharmaceuticals, Inc. announced that Sagent has acquired an FDA-approved manufacturing site in Raleigh, North Carolina, from Xellia Pharmaceuticals.
Xellia Pharmaceuticals Divests Raleigh, North Carolina Production Facilities to Sagent Pharmaceuticals
Xellia Pharmaceuticals (‘Xellia’), a specialty pharmaceutical company focused on providing important anti-infective treatments against serious and often life-threatening infections has entered into an agreement to divest Xellia’s Raleigh, North Carolina manufacturing plant to Sagent Pharmaceuticals Inc., (‘Sagent’), a leader of specialty pharmaceutical products with an emphasis on the injectable market.
Xellia Pharmaceuticals announced it has received U.S. Food and Drug Administration (FDA) approval for Premixed Vancomycin Injection in a Ready-to-Use (RTU) bag in the United States market.
Xellia Pharmaceuticals Announces the Launch of First US Market Product Vancomycin Hydrochloride for Injection, USP
Now offering Vancomycin HCl, USP 10 g and 1 g lyophilized powder in the United States market.
Xellia Pharmaceuticals Opens North American Commercial Office in Chicago Ahead of Launching Value-Added Anti-Infective Injectable Drug Products
New anti-infective products to launch in US hospital markets.
LEUKOCARE and Xellia Pharmaceuticals partner to discover innovative formulations for the development of value-added anti-infective therapies
LEUKOCARE AG and Xellia Pharmaceuticals, have entered into a global strategic partnership, where both companies will collaborate closely to discover innovative and superior formulations to support the development of Xellia’s pipeline of value-added antibiotic and antifungal products which are intended to enhance patient care.
Xellia Pharmaceuticals Appoints Craig Boyd as President, Xellia US as it Expands its Commercial Organization in Preparation for the Launch of its Value-Added Anti-Infective Drug Products
Xellia Pharmaceuticals announced that it has appointed Craig Boyd to the new leadership role of President, Xellia US.
Xellia Pharmaceuticals Reports on Strong 2017 Financial Results and Advances in the Development of its Novel Premixed Vancomycin Ready-to-Use (RTU) Bag
Xellia Pharmaceuticals reported its financial results for the year ending December 31, 2017 and provided an update on its product portfolio.
Xellia Expands Its Global Specialty Anti-Infective Product Manufacturing Capabilities With A US $25 MIllion Investment In Its Copenhagen Site
Xellia Completes Expansion Of Its Budapest Facilities, Strengthening Its Global Anti-Infective Product Capabilities
Xellia Commences Packaging And Distribution Operations At Cleveland Site after Successful FDA Inspection